{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:23:17Z","timestamp":1774527797104,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cld.2022.06.012","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:30:04Z","timestamp":1663119004000},"page":"705-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"26","author":[{"given":"Chung-Heng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9777","key":"10.1016\/j.cld.2022.06.012_bib1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cld.2012.03.012","article-title":"Approach to a patient with elevated serum alkaline phosphatase","volume":"16","author":"Siddique","year":"2012","journal-title":"Clin Liver Dis"},{"issue":"10003","key":"10.1016\/j.cld.2022.06.012_bib5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease","volume":"31","author":"Heurgue","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2022.06.012_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.012_bib12","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8537","key":"10.1016\/j.cld.2022.06.012_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.cld.2022.06.012_bib14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A\u00a0multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.cld.2022.06.012_bib15","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Pares","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib18","first-page":"759","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib19","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.012_bib23","doi-asserted-by":"crossref","first-page":"6691425","DOI":"10.1155\/2021\/6691425","article-title":"Ursodeoxycholic acid at 18-22\u00a0mg\/kg\/d showed a promising capacity for treating refractory primary biliary cholangitis","volume":"2021","author":"Xiang","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2022.06.012_bib24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","article-title":"Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis","volume":"69","author":"Harms","year":"2020","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.cld.2022.06.012_bib25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","article-title":"Systematic review: ursodeoxycholic acid--adverse effects and drug interactions","volume":"18","author":"Hempfling","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.012_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-230X-10-144","article-title":"Trends in liver transplantation for primary biliary cirrhosis in The Netherlands 1988-2008","volume":"10","author":"Kuiper","year":"2010","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2022.06.012_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2022.06.012_bib30","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib31","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis","volume":"55","author":"Osman","year":"2021","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2022.06.012_bib33","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib34","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib37","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib38","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2022.06.012_bib40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib41","doi-asserted-by":"crossref","first-page":"100191","DOI":"10.1016\/j.jhepr.2020.100191","article-title":"Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis","volume":"3","author":"Harms","year":"2021","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib43","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.012_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib45","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.jhepr.2021.100248","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D'Amato","year":"2021","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"12","key":"10.1016\/j.cld.2022.06.012_bib47","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/liv.13477","article-title":"Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: a systematic review","volume":"37","author":"Suraweera","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2022.06.012_bib48","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but Not the UK-PBC Risk Score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib49","first-page":"219","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J\u00a0Dig Dis"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"issue":"7","key":"10.1016\/j.cld.2022.06.012_bib53","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels","volume":"41","author":"Kita","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2022.06.012_bib55","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib58","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2022.06.012_bib59","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","article-title":"Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid","volume":"26","author":"Takeuchi","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.012_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","article-title":"Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"49","author":"Walker","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib63","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","article-title":"Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis","volume":"41","author":"Ohmoto","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.012_bib64","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00535-004-1583-7","article-title":"Long-term fibrate treatment for PBC","volume":"40","author":"Nakamuta","year":"2005","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00535-004-1518-3","article-title":"Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis","volume":"40","author":"Akbar","year":"2005","journal-title":"J\u00a0Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib67","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2022.06.012_bib68","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib69","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","author":"Kurihara","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"36","key":"10.1016\/j.cld.2022.06.012_bib71","first-page":"1518","article-title":"A\u00a0novel treatment for refractory primary biliary cirrhosis?","volume":"47","author":"Miyaguchi","year":"2000","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hepr.12373","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: a meta-analysis","volume":"45","author":"Zhang","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2022.06.012_bib73","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib74","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.06.012_bib75","first-page":"CD009145","article-title":"Bezafibrate for primary biliary cirrhosis","volume":"1","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"23","key":"10.1016\/j.cld.2022.06.012_bib77","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib78","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A\u00a02-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib79","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"6A","key":"10.1016\/j.cld.2022.06.012_bib80","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cld.874","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"15","author":"Lindor","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"10","key":"10.1016\/j.cld.2022.06.012_bib82","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib83","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.1840100405","article-title":"A\u00a0pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss","volume":"10","author":"Mitchison","year":"1989","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib85","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib86","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.012_bib87","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib88","first-page":"168","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"4\u20135","key":"10.1016\/j.cld.2022.06.012_bib89","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.cld.2022.06.012_bib90","first-page":"CD006000","article-title":"Azathioprine for primary biliary cirrhosis","volume":"3","author":"Gong","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"5 PT.1","key":"10.1016\/j.cld.2022.06.012_bib91","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0016-5085(76)80250-8","article-title":"A\u00a0prospective controlled trial of azathioprine in primary biliary cirrhosis","volume":"70","author":"Heathcote","year":"1976","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib92","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/0016-5085(93)91086-W","article-title":"Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups","volume":"105","author":"Christensen","year":"1993","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib93","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib94","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 Nanoparticles Induce Gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib96","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.cld.2022.06.012_bib97","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s10620-007-0003-2","article-title":"Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis","volume":"53","author":"Stanca","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib98","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","article-title":"Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid","volume":"46","author":"Stojakovic","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib99","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","article-title":"Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers","volume":"36","author":"Ritzel","year":"2002","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.012_bib100","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s10620-009-0988-9","article-title":"Statins in primary biliary cirrhosis: are they safe?","volume":"55","author":"Abu Rajab","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.cld.2022.06.012_bib101","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/liv.12191","article-title":"Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis","volume":"33","author":"Cash","year":"2013","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2022.06.012_bib102","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrgastro.2010.62","article-title":"Fatigue in primary biliary cirrhosis","volume":"7","author":"Abbas","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.012_bib103","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1007\/s10620-020-06502-0","article-title":"Understanding fatigue in primary biliary cholangitis","volume":"66","author":"Phaw","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.cld.2022.06.012_bib104","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis","volume":"25","author":"Jones","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib105","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A\u00a0randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"Silveira","year":"2017","journal-title":"Am J Ther"},{"issue":"2","key":"10.1016\/j.cld.2022.06.012_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme05020","article-title":"Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial","volume":"5","author":"Khanna","year":"2018","journal-title":"Efficacy mechanism Eval"},{"issue":"1","key":"10.1016\/j.cld.2022.06.012_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000579","article-title":"Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial","volume":"8","author":"Freer","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.012_bib108","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.012_bib109","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.dld.2019.12.119","article-title":"Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group","volume":"52","author":"D\u2019Amato","year":"2020","journal-title":"Dig Liver Dis"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:15Z","timestamp":1761069555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1089326122000502"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}